Allostery at G protein-coupled receptor homo- and heteromers: Uncharted pharmacological landscapes

Pharmacological Reviews

Volumn 62, Issue 4, 2010, Pages 701-725

  Smith, Nicola J ^a   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; CHEMOKINE RECEPTOR CXCR2; G PROTEIN COUPLED RECEPTOR; HETERODIMER; HOMODIMER; OPIATE RECEPTOR; RADIOLIGAND;

ALLOSTERISM; BINDING KINETICS; DRUG IDENTIFICATION; EXPERIMENTAL STUDY; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ALLOSTERIC SITE; ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 78650147139     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.110.002667     Document Type: Review

References (243)

1. Abdelhamid EE, Sultana M, Portoghese PS, and Takemori AE (1991) Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258:299-303.
2. Adams CL and Lawrence AJ (2007) CGP7930: a positive allosteric modulator of the GABAB receptor. CNS Drug Rev 13:308-316.
3. Albizu L, Balestre MN, Breton C, Pin JP, Manning M, Mouillac B, Barberis C, and Durroux T (2006) Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol Pharmacol 70:1783-1791.
4. Alexander SPH, Mathie A, and Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edition (2009). Br J Pharmacol 158 (Suppl 1):S1-S254.
5. Alvarez-Curto E, Pediani JD, and Milligan G (2010a) Applications of fluorescence and bioluminescence resonance energy transfer to drug discovery at G protein coupled receptors. Anal Bioanal Chem 398:167-180.
6. Alvarez-Curto E, Ward RJ, Pediani JD, and Milligan G (2010b) Ligand regulation of the quaternary organization of cell surface M3 muscarinic acetylcholine receptors analyzed by fluorescence resonance energy transfer (FRET) imaging and homogenous time-resolved FRET. J Biol Chem 285:23318-23330.
7. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, and Bouvier M (2000) Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 97:3684-3689.
8. Antony J, Kellershohn K, Mohr-AndräM, Kebig A, Prilla S, Muth M, Heller E, Disingrini T, Dallanoce C, Bertoni S, et al. (2009) Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 23:442-450.
9. Armstrong D and Strange PG (2001) Dopamine D2 receptor dimer formation: evidence from ligand binding. J Biol Chem 276:22621-22629.
10. Ayoub MA and Pfleger KD (2010) Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization. Curr Opin Pharmacol 10:44-52.
11. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Piñeyro G (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406-11411.
12. Baker JG, Hall IP, and Hill SJ (2003) Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369.
13. Ballesteros J and Ransom J (2006) In-target versus off-target allosteric modulators of GPCRs. Drug Discov Today Ther Strateg 3:445-450.
14. Banères JL and Parello J (2003) Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J Mol Biol 329:815-829.
15. Barki-Harrington L, Luttrell LM, and Rockman HA (2003) Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108:1611-1618.
16. Bhushan RG, Sharma SK, Xie Z, Daniels DJ, and Portoghese PS (2004) A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J Med Chem 47:2969-2972. (Pubitemid 38702692)
17. Birdsall NJ, Farries T, Gharagozloo P, Kobayashi S, Lazareno S, and Sugimoto M (1999) Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies. Mol Pharmacol 55:778-786. (Pubitemid 29165444)
18. Biswas P, Tambussi G, and Lazzarin A (2007) Access denied? The status of coreceptor inhibition to counter HIV entry. Expert Opin Pharmacother 8:923-933. (Pubitemid 351227480)
19. Bouvier M, Heveker N, Jockers R, Marullo S, and Milligan G (2007) BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods 4:3-4. (Pubitemid 46029461)
20. Bräuner-Osborne H, Wellendorph P, and Jensen AA (2007) Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr Drug Targets 8:169-184. (Pubitemid 46049458)
21. Brea J, Castro M, Giraldo J, López-Giménez JF, Padín JF, Quintián F, Cadavid MI, Vilaró MT, Mengod G, Berg KA, et al. (2009) Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol Pharmacol 75:1380-1391.
22. Breit A, Gagnidze K, Devi LA, Lagacé M, and Bouvier M (2006) Simultaneous activation of the delta opioid receptor (deltaOR)/sensory neuron-specific receptor-4 (SNSR-4) hetero-oligomer by the mixed bivalent agonist bovine adrenal medulla peptide 22 activates SNSR-4 but inhibits deltaOR signaling. Mol Pharmacol 70:686-696. (Pubitemid 44092329)
23. Breit A, Lagacé M, and Bouvier M (2004) Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem 279:28756-28765.
24. Bulenger S, Marullo S, and Bouvier M (2005) Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 26:131-137.
25. Cabello N, Gandía J, Bertarelli DC, Watanabe M, Lluís C, Franco R, Ferré S, Luján R, and Ciruela F (2009) Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 109:1497-1507.
26. Calebiro D, Nikolaev VO, Gagliani MC, de Filippis T, Dees C, Tacchetti C, Persani L, and Lohse MJ (2009) Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol 7:e1000172.
27. Calebiro D, Nikolaev VO, Persani L, and Lohse MJ (2010) Signaling by internalized G-protein-coupled receptors. Trends Pharmacol Sci 31:221-228.
28. Canals M, Lopez-Gimenez JF, and Milligan G (2009) Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective alpha(1b)-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers. Biochem J 417:161-172.
29. Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, Neve K, Fuxe K, Agnati LF, Woods AS, et al. (2003) Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278:46741-46749.
30. Canals M and Milligan G (2008) Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J Biol Chem 283:11424-11434.
31. Carriba P, Navarro G, Ciruela F, Ferré S, Casadó V, Agnati L, Cortés A, Mallol J, Fuxe K, Canela EI, et al. (2008) Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods 5:727-733.
32. Carrillo JJ, Pediani J, and Milligan G (2003) Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins. J Biol Chem 278:42578-42587.
33. Casadó V, Barrondo S, Spasic M, Callado LF, Mallol J, Canela E, Lluís C, Meana J, Cortés A, Sallés J, et al. (2010) G(i) protein coupling to adenosine A(1)-A(2A) receptor heteromers in human brain caudate nucleus. J Neurochem 114:972-980.
34. Casadó V, Ferrada C, Bonaventura J, Gracia E, Mallol J, Canela EI, Lluís C, Cortés A, and Franco R (2009) Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist-antagonist binding modulation. Biochem Pharmacol 78:1456-1463.
35. Chabre M, Deterre P, and Antonny B (2009) The apparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol Sci 30:182-187.
36. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, et al. (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105:10978-10983.
37. Chidiac P, Green MA, Pawagi AB, and Wells JW (1997) Cardiac muscarinic receptors. Cooperativity as the basis for multiple states of affinity. Biochemistry 36:7361-7379. (Pubitemid 27262359)
38. Chidiac P, Hebert TE, Valiquette M, Dennis M, and Bouvier M (1994) Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 45:490-499.
39. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
40. Ciruela F, Casadó V, Rodrigues RJ, Luján R, Burgueño J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J, et al. (2006a) Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26:2080-2087.
41. Ciruela F, Escriche M, Burgueno J, Angulo E, Casado V, Soloviev MM, Canela EI, Mallol J, Chan WY, Lluis C, et al. (2001) Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes. J Biol Chem 276:18345-18351. (Pubitemid 33652396)
42. Ciruela F, Ferré S, Casadó V, Cortés A, Cunha RA, Lluis C, and Franco R (2006b) Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. Cell Mol Life Sci 63:2427-2431. (Pubitemid 44722374)
43. Ciruela F, Vilardaga JP, and Fernández-Dueñas V (2010) Lighting up multiprotein complexes: lessons from GPCR oligomerization. Trends Biotechnol 28:407-415.
44. Conn PJ, Christopoulos A, and Lindsley CW (2009a) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
45. Conn PJ, Jones CK, and Lindsley CW (2009b) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 30:148-155.
46. Damian M, Martin A, Mesnier D, Pin JP, and Banères JL (2006) Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J 25:5693-5702.
47. Damian M, Mary S, Martin A, Pin JP, and Banères JL (2008) G protein activation by the leukotriene B4 receptor dimer. Evidence for an absence of trans-activation. J Biol Chem 283:21084-21092.
48. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, and Portoghese PS (2005) Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci USA 102:19208-19213.
49. Davis ME, Akera T, Brody TM, and Watson L (1977) Opiate receptor: cooperativity of binding observed in brain slices. Proc Natl Acad Sci USA 74:5764-5766.
50. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, et al. (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749-757.
51. Devi LA (2000) G-protein-coupled receptor dimers in the lime light. Trends Pharmacol Sci 21:324-326.
52. Disingrini T, Muth M, Dallanoce C, Barocelli E, Bertoni S, Kellershohn K, Mohr K, De Amici M, and Holzgrabe U (2006) Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med Chem 49:366-372.
53. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49:4721-4732.
54. Dorsch S, Klotz KN, Engelhardt S, Lohse MJ, and Bünemann M (2009) Analysis of receptor oligomerization by FRAP microscopy. Nat Methods 6:225-230.
55. Durroux T (2005) Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends Pharmacol Sci 26:376-384.
56. Eglen RM (2005) Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem 43:105-136.
57. El-Asmar L, Springael JY, Ballet S, Andrieu EU, Vassart G, and Parmentier M (2005) Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 67:460-469.
58. Ellis J, Pediani JD, Canals M, Milasta S, and Milligan G (2006) Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281:38812-38824.
59. Ernst OP, Gramse V, Kolbe M, Hofmann KP, and Heck M (2007) Monomeric G protein-coupled receptor rhodopsin in solution activates its G protein transducin at the diffusion limit. Proc Natl Acad Sci USA 104:10859-10864.
60. Fan T, Varghese G, Nguyen T, Tse R, O'Dowd BF, and George SR (2005) A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem 280:38478-38488.
61. Ferrandon S, Feinstein TN, Castro M, Wang B, Bouley R, Potts JT, Gardella TJ, and Vilardaga JP (2009) Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol 5:734-742.
62. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, et al. (2009) Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5:131-134.
63. Ferré S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueño J, Gutiérrez MA, Casadó V, Fuxe K, Goldberg SR, Lluis C, et al. (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci USA 99:11940-11945.
64. Ferré S, Quiroz C, Woods AS, Cunha R, Popoli P, Ciruela F, Lluis C, Franco R, Azdad K, and Schiffmann SN (2008) An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 14:1468-1474.
65. Ferre S, von Euler G, Johansson B, Fredholm BB, and Fuxe K (1991) Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 88:7238-7241.
66. Filipek S, Krzysko KA, Fotiadis D, Liang Y, Saperstein DA, Engel A, and Palczewski K (2004) A concept for G protein activation by G protein-coupled receptor dimers: the transducin/rhodopsin interface. Photochem Photobiol Sci 3:628-638.
67. Fonseca JM and Lambert NA (2009) Instability of a class a G protein-coupled receptor oligomer interface. Mol Pharmacol 75:1296-1299.
68. Foord SM, Jupe S, and Holbrook J (2002) Bioinformatics and type II G-protein-coupled receptors. Biochem Soc Trans 30:473-479.
69. Franco R, Casadó V, Cortés A, Ferrada C, Mallol J, Woods A, Lluis C, Canela EI, and Ferré S (2007) Basic concepts in G-protein-coupled receptor homo- and heterodimerization. ScientificWorldJournal 7:48-57.
70. Franco R, Casadó V, Cortés A, Mallol J, Ciruela F, Ferré S, Lluis C, and Canela EI (2008) G-protein-coupled receptor heteromers: function and ligand pharmacology. Br J Pharmacol 153 (Suppl 1):S90-S98.
71. Fredriksson R, Lagerström MC, Lundin LG, and Schiöth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256-1272.
72. Fredriksson R and Schiöth HB (2005) The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 67:1414-1425.
73. Galandrin S, Oligny-Longpré G, and Bouvier M (2007) The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28:423-430.
74. Galindo-Cuspinera V and Breslin PA (2006) The liaison of sweet and savory. Chem Senses 31:221-225.
75. Galvez T, Duthey B, Kniazeff J, Blahos J, Rovelli G, Bettler B, Prézeau L, and Pin JP (2001) Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J 20:2152-2159.
76. Gao F, Harikumar KG, Dong M, Lam PC, Sexton PM, Christopoulos A, Bordner A, Abagyan R, and Miller LJ (2009) Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor. Mol Pharmacol 76:264-274.
77. Gazi L, Wurch T, Lopéz-Giménez JF, Pauwels PJ, and Strange PG (2003) Pharmacological analysis of a dopamine D(2Short):G(alphao) fusion protein expressed in Sf9 cells. FEBS Lett 545:155-160.
78. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, and O'Dowd BF (2000) Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 275:26128-26135.
79. Glass M and Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327-5333.
80. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, and Devi LA (2004) A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 101:5135-5139.
81. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, and Devi LA (2000) Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J Neurosci 20:RC110.
82. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, et al. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452:93-97.
83. Goudet C, Kniazeff J, Hlavackova V, Malhaire F, Maurel D, Acher F, Blahos J, Prézeau L, and Pin JP (2005) Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators. J Biol Chem 280:24380-24385.
84. Grunder G, Carlsson A, and Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60:974-977.
85. Guo W, Shi L, Filizola M, Weinstein H, and Javitch JA (2005) Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci USA 102:17495-17500.
86. Gurevich VV and Gurevich EV (2006) The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther 110:465-502.
87. Gurevich VV and Gurevich EV (2008) How and why do GPCRs dimerize? Trends Pharmacol Sci 29:234-240.
88. 3H]raclopride to rat and human brain membranes. J Neurochem 55:2048-2057.
89. Han Y, Moreira IS, Urizar E, Weinstein H, and Javitch JA (2009) Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 5:688-695.
90. Hanson SM, Gurevich EV, Vishnivetskiy SA, Ahmed MR, Song X, and Gurevich VV (2007) Each rhodopsin molecule binds its own arrestin. Proc Natl Acad Sci USA 104:3125-3128.
91. Harding PJ, Attrill H, Boehringer J, Ross S, Wadhams GH, Smith E, Armitage JP, and Watts A (2009) Constitutive dimerization of the G-protein coupled receptor, neurotensin receptor 1, reconstituted into phospholipid bilayers. Biophys J 96:964-973.
92. Hay DL, Poyner DR, and Sexton PM (2006) GPCR modulation by RAMPs. Pharmacol Ther 109:173-197.
93. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, and Hlatky MA (1999) Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281:1927-1936.
94. Hern JA, Baig AH, Mashanov GI, Birdsall B, Corrie JE, Lazareno S, Molloy JE, and Birdsall NJ (2010) Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc Natl Acad Sci USA 107:2693-2698.
95. Hill SJ (2006) G-protein-coupled receptors: past, present and future. Br J Pharmacol 147 (Suppl 1):S27-S37.
96. Hlavackova V, Goudet C, Kniazeff J, Zikova A, Maurel D, Vol C, Trojanova J, Prézeau L, Pin JP, and Blahos J (2005) Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J 24:499-509.
97. Huang JS, Dong L, and Le Breton GC (2006) Mass-dependent signaling between G protein coupled receptors. Cell Signal 18:564-576.
98. Hudson BD, Hébert TE, and Kelly ME (2010) Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 77:1-9.
99. Ilien B, Glasser N, Clamme JP, Didier P, Piemont E, Chinnappan R, Daval SB, Galzi JL, and Mely Y (2009) Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process. J Biol Chem 284:19533-19543.
100. Jakubík J, Bacáková L, El-Fakahany EE, and Tucek S (1997) Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52:172-179.
101. Jarrahian A, Watts VJ, and Barker EL (2004) D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 308:880-886.
102. Jastrzebska B, Fotiadis D, Jang GF, Stenkamp RE, Engel A, and Palczewski K (2006) Functional and structural characterization of rhodopsin oligomers. J Biol Chem 281:11917-11922.
103. Jiang P, Cui M, Zhao B, Liu Z, Snyder LA, Benard LM, Osman R, Margolskee RF, and Max M (2005) Lactisole interacts with the transmembrane domains of human T1R3 to inhibit sweet taste. J Biol Chem 280:15238-15246.
104. Jockers R, Maurice P, Boutin JA, and Delagrange P (2008) Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 154:1182-1195.
105. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, et al. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28:10422-10433.
106. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, Yao WJ, Johnson M, Gunwaldsen C, Huang LY, et al. (1998) GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396:674-679.
107. Jordan BA and Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697-700.
108. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, and Devi LA (2001) Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 98:343-348.
109. Kara E, Lin H, and Strange PG (2010) Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics. J Neurochem 112:1442-1453.
110. Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, Mosbacher J, Bischoff S, Kulik A, Shigemoto R, et al. (1998) GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 396:683-687.
111. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, and Glass M (2005) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67:1697-1704.
112. Kenakin T (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 28:407-415.
113. Kenakin T (2008) Functional selectivity in GPCR modulator screening. Comb Chem High Throughput Screen 11:337-343.
114. Kenakin T (2009a) Interrogating 7TM receptors: does texture in the question yield greater texture in the answer? J Recept Signal Transduct Res 29:132-139.
115. Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
116. Kenakin TP (2009b) '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30:460-469.
117. Khelashvili G, Dorff K, Shan J, Camacho-Artacho M, Skrabanek L, Vroling B, Bouvier M, Devi LA, George SR, Javitch JA, et al. (2010) GPCR-OKB: The G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics 26:1804-1805.
118. Kobilka BK and Deupi X (2007) Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28:397-406.
119. Korzh A, Keren O, Gafni M, Bar-Josef H, and Sarne Y (2008) Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell. Brain Res 1189:23-32.
120. Kostenis E, Waelbroeck M, and Milligan G (2005) Techniques: promiscuous Galpha proteins in basic research and drug discovery. Trends Pharmacol Sci 26:595-602.
121. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, and Morikawa K (2000) Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407:971-977.
122. Lagerström MC and Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339-357.
123. Lambert NA (2010) GPCR dimers fall apart. Sci Signal 3:pe12.
124. Langmead CJ and Christopoulos A (2006) Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 27:475-481.
125. Lavoie C and Hébert TE (2003) Pharmacological characterization of putative beta1-beta2-adrenergic receptor heterodimers. Can J Physiol Pharmacol 81:186-195.
126. Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, Zhu WZ, Xiao RP, Lakatta EG, Bouvier M, et al. (2002) Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem 277:35402-35410.
127. Lazareno S, Birdsall B, Fukazawa T, Gharagozloo P, Hashimoto T, Kuwano H, Popham A, Sugimoto M, and Birdsall NJ (1999) Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors. Life Sci 64:519-526.
128. Lazareno S, Dolezal V, Popham A, and Birdsall NJ (2004) Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol 65:257-266.
129. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389.
130. Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lança AJ, O'Dowd BF, and George SR (2004) Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279:35671-35678.
131. Lefkowitz RJ (2004) Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci 25:413-422.
132. Lefkowitz RJ (2007a) Seven transmembrane receptors: a brief personal retrospective. Biochim Biophys Acta 1768:748-755.
133. Lefkowitz RJ (2007b) Seven transmembrane receptors: something old, something new. Acta Physiol (Oxf) 1970:9-19.
134. Lei ZM, Mishra S, Zou W, Xu B, Foltz M, Li X, and Rao CV (2001) Targeted disruption of luteinizing hormone/human chorionic gonadotropin receptor gene. Mol Endocrinol 15:184-200.
135. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P, and Jockers R (2006) The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J 25:3012-3023.
136. Li X, Staszewski L, Xu H, Durick K, Zoller M, and Adler E (2002) Human receptors for sweet and umami taste. Proc Natl Acad Sci USA 99:4692-4696.
137. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, and Engel A (2003) Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J Biol Chem 278:21655-21662.
138. Limbird LE, Meyts PD, and Lefkowitz RJ (1975) Beta-adrenergic receptors: evidence for negative cooperativity. Biochem Biophys Res Commun 64:1160-1168.
139. Liu J, Maurel D, Etzol S, Brabet I, Ansanay H, Pin JP, and Rondard P (2004) Molecular determinants involved in the allosteric control of agonist affinity in the GABAB receptor by the GABAB2 subunit. J Biol Chem 279:15824-15830.
140. Lopez-Gimenez JF, Canals M, Pediani JD, and Milligan G (2007) The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function. Mol Pharmacol 71:1015-1029.
141. Lopez-Gimenez JF, Vilaró MT, and Milligan G (2008) Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation. Mol Pharmacol 74:1278-1291.
142. Lu ZL, Saldanha JW, and Hulme EC (2002) Seven-transmembrane receptors: crystals clarify. Trends Pharmacol Sci 23:140-146.
143. Maggio R, Aloisi G, Silvano E, Rossi M, and Millan MJ (2009) Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. Parkinsonism Relat Disord 15 (Suppl 4):S2-S7.
144. Maggio R and Millan MJ (2010) Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol 10:100-107.
145. Maggio R, Scarselli M, Novi F, Millan MJ, and Corsini GU (2003) Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 87:631-641.
146. Maggio R, Vogel Z, and Wess J (1993) Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. Proc Natl Acad Sci USA 90:3103-3107.
147. Marcellino D, Ferré S, Casadó V, Cortés A, Le Foll B, Mazzola C, Drago F, Saur O, Stark H, Soriano A, et al. (2008) Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283:26016-26025.
148. Marianayagam NJ, Sunde M, and Matthews JM (2004) The power of two: protein dimerization in biology. Trends Biochem Sci 29:618-625.
149. Marshall FH, Jones KA, Kaupmann K, and Bettler B (1999) GABAB receptors - the first 7TM heterodimers. Trends Pharmacol Sci 20:396-399.
150. Maurel D, Comps-Agrar L, Brock C, Rives ML, Bourrier E, Ayoub MA, Bazin H, Tinel N, Durroux T, Prézeau L, et al. (2008) Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat Methods 5:561-567.
151. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
152. McVey M, Ramsay D, Kellett E, Rees S, Wilson S, Pope AJ, and Milligan G (2001) Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human delta-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. J Biol Chem 276:14092-14099.
153. Mercier JF, Salahpour A, Angers S, Breit A, and Bouvier M (2002) Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem 277:44925-44931.
154. Mesnier D and Banères JL (2004) Cooperative conformational changes in a G-protein-coupled receptor dimer, the leukotriene B(4) receptor BLT1. J Biol Chem 279:49664-49670.
155. Milligan G (2000) Insights into ligand pharmacology using receptor-G-protein fusion proteins. Trends Pharmacol Sci 21:24-28.
156. Milligan G (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66:1-7.
157. Milligan G (2006) G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discov Today 11:541-549.
158. Milligan G (2008) A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization. Br J Pharmacol 153 (Suppl 1):S216-S229.
159. Milligan G (2009) G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol 158:5-14.
160. Milligan G (2010a) GPCR-G Protein Fusions: Use in Functional Dimerization Analysis. Cambridge University Press, New York.
161. Milligan G (2010b) The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. Curr Opin Pharmacol 10:23-29.
162. Milligan G and Bouvier M (2005) Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J 272:2914-2925. (Pubitemid 40904680)
163. Milligan G, Feng GJ, Ward RJ, Sartania N, Ramsay D, McLean AJ, and Carrillo JJ (2004) G protein-coupled receptor fusion proteins in drug discovery. Curr Pharm Des 10:1989-2001.
164. Milligan G and Kostenis E (2006) Heterotrimeric G-proteins: a short history. Br J Pharmacol 147 (Suppl 1):S46-S55.
165. Milligan G, Parenty G, Stoddart LA, and Lane JR (2007) Novel pharmacological applications of G-protein-coupled receptor-G protein fusions. Curr Opin Pharmacol 7:521-526.
166. Milligan G and Smith NJ (2007) Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 28:615-620.
167. Moreno JL, Sealfon SC, and González-Maeso J (2009) Group II metabotropic glutamate receptors and schizophrenia. Cell Mol Life Sci 66:3777-3785.
168. Morgan TO, Anderson AI, and MacInnis RJ (2001) ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 14:241-247.
169. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, and Seuwen K (2009) Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5:428-434.
170. Muto T, Tsuchiya D, Morikawa K, and Jingami H (2007) Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc Natl Acad Sci USA 104:3759-3764.
171. Nagano N (2006) Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 109:339-365.
172. Navarro G, Ferré S, Cordomi A, Moreno E, Mallol J, Casadó V, Cortés A, Hoffmann H, Ortiz J, Canela EI, et al. (2010) Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J Biol Chem 285:27346-27359.
173. Novi F, Millan MJ, Corsini GU, and Maggio R (2007) Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by cotransfection of D(3) receptors: potential role of heterodimer formation. J Neurochem 102:1410-1424.
174. Novi F, Scarselli M, Corsini GU, and Maggio R (2004) The paired activation of the two components of the muscarinic M3 receptor dimer is required for induction of ERK1/2 phosphorylation. J Biol Chem 279:7476-7486.
175. Palczewski K (2010) Oligomeric forms of G protein-coupled receptors (GPCRs). Trends Biochem Sci doi: 10.1016/j.tibs.2010.05.002.
176. Parenty G, Appelbe S, and Milligan G (2008) CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem J 412:245-256.
177. Park PS, Sum CS, Pawagi AB, and Wells JW (2002) Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. Biochemistry 41:5588-5604.
178. Pascal G and Milligan G (2005) Functional complementation and the analysis of opioid receptor homodimerization. Mol Pharmacol 68:905-915.
179. Perez DM (2003) The evolutionarily triumphant G-protein-coupled receptor. Mol Pharmacol 63:1202-1205.
180. Perez DM (2005) From plants to man: the GPCR "tree of life". Mol Pharmacol 67:1383-1384.
181. Perron A, Chen ZG, Gingras D, Dupre DJ, Stankova J, and Rola-Pleszczynski M (2003) Agonist-independent desensitization and internalization of the human platelet-activating factor receptor by coumermycin-gyrase B-induced dimerization. J Biol Chem 278:27956-27965.
182. Pfeiffer M, Kirscht S, Stumm R, Koch T, Wu D, Laugsch M, Schröder H, Höllt V, and Schulz S (2003) Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization. J Biol Chem 278:51630-51637.
183. Pfeiffer M, Koch T, Schröder H, Klutzny M, Kirscht S, Kreienkamp HJ, Höllt V, and Schulz S (2001) Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 276:14027-14036.
184. Pfeiffer M, Koch T, Schröder H, Laugsch M, Höllt V, and Schulz S (2002) Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277:19762-19772.
185. Pfleger KD (2009) Analysis of protein-protein interactions using bioluminescence resonance energy transfer. Methods Mol Biol 574:173-183.
186. Pfleger KD, Dalrymple MB, Dromey JR, and Eidne KA (2007) Monitoring interactions between G-protein-coupled receptors and beta-arrestins. Biochem Soc Trans 35:764-766.
187. Pfleger KD and Eidne KA (2006) Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat Methods 3:165-174.
188. Pin JP, Galvez T, and Prézeau L (2003) Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 98:325-354.
189. Pin JP, Kniazeff J, Liu J, Binet V, Goudet C, Rondard P, and Prézeau L (2005) Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J 272:2947-2955.
190. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, Parmentier M, et al. (2007) International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 59:5-13.
191. Pin JP and Prézeau L (2007) Allosteric modulators of GABA(B) receptors: mechanism of action and therapeutic perspective. Curr Neuropharmacol 5:195-201.
192. Powell-Jones CH, Thomas CG Jr, and Nayfeh SN (1979) Contribution of negative cooperativity to the thyrotropin-receptor interaction in normal human thyroid: kinetic evaluation. Proc Natl Acad Sci USA 76:705-709.
193. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, and Foord SM (2002) International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54:233-246.
194. Prezeau L, Rives ML, Comps-Agrar L, Maurel D, Kniazeff J, and Pin JP (2010) Functional crosstalk between GPCRs: with or without oligomerization. Curr Opin Pharmacol 10:6-13.
195. Ramsay D, Kellett E, McVey M, Rees S, and Milligan G (2002) Homo- and heterooligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J 365:429-440.
196. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O'Dowd BF, and George SR (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci USA 104:654-659.
197. Rees S, Morrow D, and Kenakin T (2002) GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 8:261-268.
198. Rios C, Gomes I, and Devi LA (2006) mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148:387-395.
199. Rivero-Müller A, Chou YY, Ji I, Lajic S, Hanyaloglu AC, Jonas K, Rahman N, Ji TH, and Huhtaniemi I (2010) Rescue of defective G protein-coupled receptor function in vivo by intermolecular cooperation. Proc Natl Acad Sci USA 107:2319-2324.
200. Rovira X, Pin JP, and Giraldo J (2010) The asymmetric/symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signalling pathways. Trends Pharmacol Sci 31:15-21.
201. Rozenfeld R and Devi LA (2010) Receptor heteromerization and drug discovery. Trends Pharmacol Sci 31:124-130.
202. Saenz del Burgo L and Milligan G (2010a) Heterodimerisation of G protein-coupled receptors: implications for drug design and ligand screening. Expert Opin Drug Discov 5:461-474.
203. Saenz del Burgo L and Milligan G (2010b) Ligand Regulation of GPCR Quaternary Structure. Royal Society of Chemistry, London.
204. Sartania N, Appelbe S, Pediani JD, and Milligan G (2007) Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric beta2-adrenoceptor. Cell Signal 19:1928-1938.
205. Schwartz TW and Holst B (2006) Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 26:107-128.
206. Seifert R, Wenzel-Seifert K, and Kobilka BK (1999) GPCR-Galpha fusion proteins: molecular analysis of receptor-G-protein coupling. Trends Pharmacol Sci 20:383-389.
207. Sexton PM, Poyner DR, Simms J, Christopoulos A, and Hay DL (2009) Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov Today 14:413-419.
208. Shapira M, Vogel Z, and Sarne Y (2000) Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cell Mol Neurobiol 20:291-304.
209. Sharma SK, Jones RM, Metzger TG, Ferguson DM, and Portoghese PS (2001) Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5′- to 6′-position of naltrindole. J Med Chem 44:2073-2079.
210. Skrabanek L, Murcia M, Bouvier M, Devi L, George SR, Lohse MJ, Milligan G, Neubig R, Palczewski K, Parmentier M, et al. (2007) Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics 8:177.
211. Snook LA, Milligan G, Kieffer BL, and Massotte D (2006) Mu-delta opioid receptor functional interaction: Insight using receptor-G protein fusions. J Pharmacol Exp Ther 318:683-690.
212. Snook LA, Milligan G, Kieffer BL, and Massotte D (2008) Co-expression of mu and delta opioid receptors as receptor-G protein fusions enhances both mu and delta signalling via distinct mechanisms. J Neurochem 105:865-873.
213. Sohy D, Parmentier M, and Springael JY (2007) Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem 282:30062-30069.
214. Soudijn W, Van Wijngaarden I, and IJzerman AP (2004) Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discov Today 9:752-758.
215. Springael JY, Le Minh PN, Urizar E, Costagliola S, Vassart G, and Parmentier M (2006) Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol 69:1652-1661.
216. Springael JY, Urizar E, Costagliola S, Vassart G, and Parmentier M (2007) Allosteric properties of G protein-coupled receptor oligomers. Pharmacol Ther 115:410-418.
217. Stanasila L, Perez JB, Vogel H, and Cotecchia S (2003) Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. J Biol Chem 278:40239-40251.
218. Steinfeld T, Mammen M, Smith JA, Wilson RD, and Jasper JR (2007) A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol 72:291-302.
219. Storez H, Scott MG, Issafras H, Burtey A, Benmerah A, Muntaner O, Piolot T, Tramier M, Coppey-Moisan M, Bouvier M, et al. (2005) Homo- and heterooligomerization of beta-arrestins in living cells. J Biol Chem 280:40210-40215.
220. Sum CS, Pyo N, and Wells JW (2001) Apparent capacity of cardiac muscarinic receptors for different radiolabeled antagonists. Biochem Pharmacol 62:829-851.
221. Suzuki Y, Moriyoshi E, Tsuchiya D, and Jingami H (2004) Negative cooperativity of glutamate binding in the dimeric metabotropic glutamate receptor subtype 1. J Biol Chem 279:35526-35534.
222. Svendsen AM, Vrecl M, Ellis TM, Heding A, Kristensen JB, Wade JD, Bathgate RA, De Meyts P, and Nøhr J (2008a) Cooperative binding of insulin-like Peptide 3 to a dimeric relaxin family peptide receptor 2. Endocrinology 149:1113-1120.
223. Svendsen AM, Zalesko A, Kønig J, Vrecl M, Heding A, Kristensen JB, Wade JD, Bathgate RA, De Meyts P, and Nøhr J (2008b) Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1. Mol Cell Endocrinol 296:10-17.
224. Tadori Y, Forbes RA, McQuade RD, and Kikuchi T (2008) Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 597:27-33.
225. Terrillon S and Bouvier M (2004) Roles of G-protein-coupled receptor dimerization. EMBO Rep 5:30-34.
226. Tubio MR, Fernandez N, Fitzsimons CP, Copsel S, Santiago S, Shayo C, Davio C, and Monczor F (2010) Expression of a G protein-coupled receptor (GPCR) leads to attenuation of signaling by other GPCRs: experimental evidence for a spontaneous GPCR constitutive inactive form. J Biol Chem 285:14990-14998.
227. Urizar E, Montanelli L, Loy T, Bonomi M, Swillens S, Gales C, Bouvier M, Smits G, Vassart G, and Costagliola S (2005) Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J 24:1954-1964.
228. Valant C, Sexton PM, and Christopoulos A (2009) Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol Interv 9:125-135.
229. Vilardaga JP, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z, and Lohse MJ (2008) Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol 4:126-131.
230. Vivo M, Lin H, and Strange PG (2006) Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor. Mol Pharmacol 69:226-235.
231. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS, and Whistler JL (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci USA 102:9050-9055.
232. White JF, Grodnitzky J, Louis JM, Trinh LB, Shiloach J, Gutierrez J, Northup JK, and Grisshammer R (2007) Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction. Proc Natl Acad Sci USA 104:12199-12204.
233. White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, Barnes AA, Emson P, Foord SM, and Marshall FH (1998) Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 396:679-682.
234. Whorton MR, Bokoch MP, Rasmussen SG, Huang B, Zare RN, Kobilka B, and Sunahara RK (2007) A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci USA 104:7682-7687.
235. Whorton MR, Jastrzebska B, Park PS, Fotiadis D, Engel A, Palczewski K, and Sunahara RK (2008) Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J Biol Chem 283:4387-4394.
236. Wreggett KA and Wells JW (1995) Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J Biol Chem 270:22488-22499.
237. Wurch T and Pauwels PJ (2001) Analytical pharmacology of G protein-coupled receptors by stoichiometric expression of the receptor and G(alpha) protein subunits. J Pharmacol Toxicol Methods 45:3-16.
238. Xu H, Staszewski L, Tang H, Adler E, Zoller M, and Li X (2004) Different functional roles of T1R subunits in the heteromeric taste receptors. Proc Natl Acad Sci USA 101:14258-14263.
239. Xu J, He J, Castleberry AM, Balasubramanian S, Lau AG, and Hall RA (2003) Heterodimerization of alpha 2A- and beta 1-adrenergic receptors. J Biol Chem 278:10770-10777.
240. Xu TR, Baillie GS, Bhari N, Houslay TM, Pitt AM, Adams DR, Kolch W, Houslay MD, and Milligan G (2008) Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochem J 413:51-60.
241. Zhang FP, Poutanen M, Wilbertz J, and Huhtaniemi I (2001) Normal prenatal but arrested postnatal sexual development of luteinizing hormone receptor knockout (LuRKO) mice. Mol Endocrinol 15:172-183.
242. Zhang S, Yekkirala A, Tang Y, and Portoghese PS (2009) A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors. Bioorg Med Chem Lett 19:6978-6980.
243. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, and Pintar JE (1999) Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24:243-252.